(Rockville, MD) MEDIPOST America Inc. announced US FDA approval of a phase 1/2 clinical trial for PNEUMOSTEM for newborn infants who will be at high risk for developing bronchopulmonary dysplasia (BPD).
Medipost America Clears Phase For IND Stem Cell Clinical Trial (Business Wire)
